Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Jun 26;19(1):558.
doi: 10.1186/s12879-019-4209-7.

Management of amphotericin-induced phlebitis among HIV patients with cryptococcal meningitis in a resource-limited setting: a prospective cohort study

Cynthia Ahimbisibwe  1 , Richard Kwizera  2 , Jane Frances Ndyetukira  1 , Florence Kugonza  1 , Alisat Sadiq  1 , Kathy Huppler Hullsiek  3 , Darlisha A Williams  1   4 , Joshua Rhein  1   4 , David R Boulware  4 , David B Meya  1   4   5
Affiliations
Clinical Trial

Management of amphotericin-induced phlebitis among HIV patients with cryptococcal meningitis in a resource-limited setting: a prospective cohort study

Cynthia Ahimbisibwe et al. BMC Infect Dis. .

Abstract

Background: Amphotericin-induced phlebitis is a common infusion-related reaction in patients managed for cryptococcal meningitis. High-quality nursing care is critical component to successful cryptococcosis treatment. We highlight the magnitude and main approaches in the management of amphotericin-induced phlebitis and the challenges faced in resource-limited settings.

Methods: We prospectively determined the incidence of amphotericin-induced phlebitis during clinical trials in Kampala, Uganda from 2013 to 2018. We relate practical strategies and challenges faced in clinical management of phlebitis.

Results: Overall, 696 participants were diagnosed with HIV-related cryptococcal meningitis. Participants received 7-14 doses of intravenous (IV) amphotericin B deoxycholate 0.7-1.0 mg/kg/day for induction therapy through peripheral IV lines at a concentration of 0.1 mg/mL in 5% dextrose. Overall, 18% (125/696) developed amphotericin-induced phlebitis. We used four strategies to minimize/prevent the occurrence of phlebitis. First, after every dose of amphotericin, we gave one liter of intravenous normal saline. Second, we rotated IV catheters every three days. Third, we infused IV amphotericin over 4 h. Finally, early ambulation was encouraged to minimize phlebitis. To alleviate phlebitis symptoms, warm compresses were used. In severe cases, treatment included topical diclofenac gel and oral anti-inflammatory medicines. Antibiotics were used only when definite signs of infection developed. Patient/caregivers' education was vital in implementing these management strategies. Major challenges included implementing these interventions in participants with altered mental status and limited access to topical and oral anti-inflammatory medicines in resource-limited settings.

Conclusions: Amphotericin-induced phlebitis is common with amphotericin, yet phlebitis is a preventable complication even in resource-limited settings.

Trial registration: The ASTRO-CM trial was registered prospectively. ClincalTrials.gov : NCT01802385 ; Registration date: March 1, 2013; Last verified: February 14, 2018.

Keywords: Amphotericin B; Cryptococcal infection; HIV; Nursing; Phlebitis; Sub-Saharan Africa; Thrombophlebitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Durski KN, Kuntz KM, Yasukawa K, Virnig BA, Meya DB, Boulware DR. Cost-effective diagnostic checklists for meningitis in resource-limited settings. J Acquir Immune Defic Syndr. 2013;63(3):e101–e108. doi: 10.1097/QAI.0b013e31828e1e56. - DOI - PMC - PubMed
    1. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, Denning DW, Loyse A, Boulware DR. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873–881. doi: 10.1016/S1473-3099(17)30243-8. - DOI - PMC - PubMed
    1. Parkes-Ratanshi R, Achan B, Kwizera R, Kambugu A, Meya D, Denning D. Cryptococcal disease and the burden of other fungal diseases in Uganda; where are the knowledge gaps and how can we fill them? Mycoses. 2015;58(S5):85–93. doi: 10.1111/myc.12387. - DOI - PubMed
    1. Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children [http://www.who.int/hiv/pub/guidelines/cryptococcal-disease/en/]. - PubMed
    1. Enoch D, Ludlam H, Brown N. Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol. 2006;55(7):809–818. doi: 10.1099/jmm.0.46548-0. - DOI - PubMed

MeSH terms

Associated data